The vast majority of genome-wide association studies (GWASs) are performed in Europeans, and their transferability to other populations is dependent on many factors (e.g., linkage disequilibrium, allele frequencies, genetic architecture). As medical genomics studies become increasingly large and diverse, gaining insights into population history and consequently the transferability of disease risk measurement is critical. Here, we disentangle recent population history in the widely used 1000 Genomes Project reference panel, with an emphasis on populations underrepresented in medical studies. To examine the transferability of single-ancestry GWASs, we used published summary statistics to calculate polygenic risk scores for eight well-studied phenotypes. We identify directional inconsistencies in all scores; for example, height is predicted to decrease with genetic distance from Europeans, despite robust anthropological evidence that West Africans are as tall as Europeans on average. To gain deeper quantitative insights into GWAS transferability, we developed a complex trait coalescent-based simulation framework considering effects of polygenicity, causal allele frequency divergence, and heritability. As expected, correlations between true and inferred risk are typically highest in the population from which summary statistics were derived. We demonstrate that scores inferred from European GWASs are biased by genetic drift in other populations even when choosing the same causal variants and that biases in any direction are possible and unpredictable. This work cautions that summarizing findings from large-scale GWASs may have limited portability to other populations using standard approaches and highlights the need for generalized risk prediction methods and the inclusion of more diverse individuals in medical genomics.
Introduction
The majority of genome-wide association studies (GWASs) have been performed in populations of European descent. [1] [2] [3] [4] An open question in medical genomics is the degree to which these results transfer to new populations. GWASs have yielded tens of thousands of common genetic variants significantly associated with human medical and evolutionary phenotypes, most of which have replicated in other ethnic groups. [5] [6] [7] However, GWASs are optimally powered to discover common variant associations, and the European bias in GWASs results in associated SNPs with higher minor allele frequencies on average compared to other populations. The predictive power of GWAS findings and genetic diagnostic accuracy in non-Europeans are therefore limited by population differences in allele frequencies and linkage disequilibrium structure. For example, a previous study showed that the accuracy of breeding values and genomic prediction decays approximately linearly with increasing divergence between the discovery and target population. 8 Additionally, multiple individuals with African ancestry have received false positive misdiagnoses of hypertrophic cardiomyopathy that would have been prevented with the inclusion of even small numbers of African Americans in these studies. 9 Further, a previous study finding that 96% of GWAS participants are of European descent 1 has recently been updated; although the non-European proportion of GWAS participants has increased to nearly 20%, this is primarily driven by Asian individuals, and the proportion of individuals with African and Hispanic/Latino ancestry in GWASs has remained essentially unchanged.
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As GWAS sample sizes grow to hundreds of thousands of samples, they also become better powered to detect rare variant associations. [10] [11] [12] Large-scale sequencing studies have demonstrated that rare variants show stronger geographic clustering than common variants. [13] [14] [15] Rare, disease-associated variants are therefore expected to track with recent population demography and/or be population restricted. 14, [16] [17] [18] As the next era of GWASs expands to evaluate the disease-associated role of rare variants, it is not only scientifically imperative to include multi-ethnic populations, it is also likely that such studies will encounter increasing genetic heterogeneity in very large study populations. A comprehensive understanding of the genetic diversity and demographic history of multiethnic populations is critical for appropriate applications of GWASs and ultimately for ensuring that genetics does not contribute to or enhance health disparities.
The most recent release of the 1000 Genomes Project (phase 3) provides one of the largest global reference panels of whole-genome sequencing data, enabling a broad survey of human genetic variation. 19 The depth The dawn of the GWAS era saw limited success in identifying genome-wide significant loci associated with disease, and a major endeavor to better understand the genetic architecture of complex traits emerged. The peaks that met genome-wide significance typically did not explain a significant fraction of the phenotypic variance, and a major goal to estimate how many more signals remained yet to be discovered arose; this objective ushered in a wave of methodological development in heritability, linear mixed models, and polygenic risk prediction, as discussed and reviewed extensively elsewhere.
11,48-56 Numerous complex traits have been studied with cohort sizes in the hundreds of thousands, and yet in each case there are many more signals that improve prediction accuracy than meet genome-wide significance. 48, [57] [58] [59] For example, including only genome-wide significant loci in the prediction of schizophrenia explains <3% of the phenotypic variance, whereas loci meeting the significance threshold that optimally balances signal versus noise (in this case, p % 0.1) in the meta-analysis explains considerably more (>18%) of the phenotypic variance. 11 Because the prediction accuracy, which is usually measured via prediction R 2 , Nagelkerke's R 2 , or receiver operator curve AUC, of polygenic risk scores is currently low for most traits, 56 genetic risk prediction is not clinically viable at present, but polygenic risk scores have nonetheless repeatedly proven valuable in research contexts across a multitude of complex traits 11, 48, [60] [61] [62] [63] [64] [65] and will become increasingly useful as GWAS sample sizes grow. 59 Additionally, several methodological advancements to the standard approach have recently been undertaken. 58, [66] [67] [68] In this study, we explore the impact of population diversity on the landscape of variation underlying human traits. We infer demographic history for the global populations in the 1000 Genomes Project, focusing particularly on admixed populations from the Americas, which are underrepresented in medical genetic studies. 4 We disentangle local ancestry to infer the ancestral origins of these populations. We link this work to ongoing efforts to improve study design and disease variant discovery by quantifying biases in clinical databases and GWASs in diverse and admixed populations. These biases have a striking impact on genetic risk prediction; for example, a previous study calculated polygenic risk scores for schizophrenia in East Asians and Africans based on GWAS summary statistics derived from a European cohort and found that prediction accuracy was reduced by more than 50% in non-European populations. 67 To disentangle the role of demography on polygenic risk prediction derived from single-ancestry GWASs, we designed a coalescent-based simulation framework reflecting modern human population history and show that polygenic risk scores derived from European GWASs are biased when applied to diverged populations. Specifically, we identify reduced variance in risk prediction with increasing divergence from Europe reflecting decreased overall variance explained, and demonstrate that an enrichment of low-frequency risk and high-frequency protective alleles contribute to an overall protective shift in European inferred risk on average across traits. Our results highlight the need for the inclusion of more diverse populations in GWASs as well as genetic risk prediction methods improving transferability across populations.
Material and Methods

Ancestry Deconvolution
We used the phased haplotypes from the 1000 Genomes consortium. We phased reference haplotypes from 43 Native American samples from Mao et al. 69 inferred to have >0.99
Native ancestry in ADMIXTURE using SHAPEIT2 (v.2.r778), 70 then merged the haplotypes using scripts made publicly available. These combined phased haplotypes were used as input to the PopPhased version of RFMix v.1.5.4 71 with the following flags: -w 0.2, -e 1, -n 5, --use-reference-panels-in-EM, --forwardbackward EM. The node size of 5 was selected to reduce bias in
